MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
194.38
-10.27
-5.02%
After Hours: 193.90 -0.48 -0.25% 17:47 04/25 EDT
OPEN
200.63
PREV CLOSE
204.65
HIGH
200.97
LOW
190.22
VOLUME
707.19K
TURNOVER
0
52 WEEK HIGH
322.67
52 WEEK LOW
119.76
MARKET CAP
4.08B
P/E (TTM)
-9.7223
1D
5D
1M
3M
1Y
5Y
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Madrigal Pharmaceuticals, Inc. Recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035. The company will have to overcome two challenges to maintain its "first mover" advantage in the market. Madrigal has to manage the launch of Rezdiffra and keep an eye on future competitors.
Seeking Alpha · 1d ago
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 2d ago
B of A Securities Initiates Coverage of Madrigal Pharmaceuticals (MDGL) with Underperform Recommendation
NASDAQ · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport
U.S. Stocks rose on Monday in choppy trading. The Dow Jones Industrial Average was up 1.01% at 38,371.51. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Vanda Pharma. The market is looking ahead to major tech earnings and a key inflation print this week. AZZ, Vanda Pharmaceutical and Matterport are up on the day.
Reuters · 3d ago
Madrigal Pharmaceuticals Becomes Oversold (MDGL)
NASDAQ · 3d ago
United Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Rating
TipRanks · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardinal Health (CAH) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 3d ago
REFILE-BUZZ-Madrigal Pharma falls as BofA initiates coverage with 'underperform' rating
Madrigal Pharma falls as BofA initiates coverage with 'underperform' rating. Shares of Madrigal Pharmaceuticals MDGL.O fall 6.3% to $198.69. Bofa forecasts peak sales of $4.1 billion below consensus estimates.
Reuters · 3d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.